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Comparison of acute non-visual 
bright light responses in patients 
with optic nerve disease, glaucoma 
and healthy controls
M. Münch1,†, L. Léon2, S. Collomb2 & A. Kawasaki2
This study examined the effect of optic nerve disease, hence retinal ganglion cell loss, on non-
visual functions related to melanopsin signalling. Test subjects were patients with bilateral visual 
loss and optic atrophy from either hereditary optic neuropathy (n = 11) or glaucoma (n = 11). We 
measured melatonin suppression, subjective sleepiness and cognitive functions in response to 
bright light exposure in the evening. We also quantified the post-illumination pupil response to 
a blue light stimulus. All results were compared to age-matched controls (n = 22). Both groups of 
patients showed similar melatonin suppression when compared to their controls. Greater melatonin 
suppression was intra-individually correlated to larger post-illumination pupil response in patients 
and controls. Only the glaucoma patients demonstrated a relative attenuation of their pupil 
response. In addition, they were sleepier with slower reaction times during nocturnal light exposure. 
In conclusion, glaucomatous, but not hereditary, optic neuropathy is associated with reduced acute 
light effects. At mild to moderate stages of disease, this is detected only in the pupil function and 
not in responses conveyed via the retinohypothalamic tract such as melatonin suppression.
Melanopsin-mediated photoreception within intrinsically photosensitive retinal ganglion cells (ipRGCs) 
is an irradiance detection system in the eye that operates in parallel with the luminance encoding system 
of rods and cones1–3. The melanopsin system in mammals is involved in several non-visual, light-mediated 
functions such as regulation of pupil size, circadian photoentrainment, hormonal secretion, sleep regula-
tion, mood and cognitive performance4–7. Axons from ipRGCs project directly to various nuclei in deep 
brain centers8. The most abundant of these monosynaptic projections forms the retinohypothalamic tract 
(RHT) and synapses at the suprachiasmatic nucleus (SCN) of the hypothalamus9,10. The SCN is consid-
ered the master circadian pacemaker, and the melanopsin system via the RHT is the primary means 
by which the endogenous biologic clock is entrained to environmental light-dark cycles1,2. In addition 
to the circadian effects, light also has acute effects, which occur immediately after onset of light. These 
include nocturnal suppression of the pineal hormone melatonin11, reduced subjective sleepiness, greater 
attentional vigilance and improved neurobehavioral performance12,13.
The ipRGCs also form another important monosynaptic pathway to the brain, the retinotectal tract 
(RTT) which synapses at the pretectal olivary nuclei of the dorsal midbrain2. The RTT is the source of 
all afferent pupillomotor input from the eye for the pupil light reflex4,14. While ipRGCs are not required 
for classical visual functions, they do receive extrinsic input from rods and cones15,16 which can modu-
late signalling in the RTT. In humans, rods and cones are suited for detection of rapid changes in light 
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and are primarily responsible for initiating the immediate pupil contraction to an abrupt increase in 
illumination17.
Light at high irradiance (> 13 log quanta/cm2/s retinal irradiance), particularly in the short wave-
length range, strongly activates melanopsin18,19. In the absence of rod and cone function, the pupil in 
mammals (rodents and primates) and humans can still react to light via intrinsic, melanopsin-mediated 
photoreception of ipRGCs4,20,21. On pupillographic recordings in macaque monkeys whose rod and 
cone activity has been pharmacologically blocked, the distinctive feature of melanopsin to the pupil 
response is a sustained contraction that persists after light offset18,20,22. This behaviour has been termed 
the post-illumination pupil response, or PIPR18,22–25. Despite the relative paucity of ipRGCs (about 3000 
per eye in human and non-human primates)19,26, there is surprising diversity in their anatomic morphol-
ogy, molecular expression and kinetics of photic response26–31. In mice, at least five subtypes of ipRGCs 
have been identified. While a strict subdivision of labor amongst ipRGC subtypes is not established, there 
is nascent evidence suggesting differential roles for ipRGC subtypes with M1 subtype primarily dedicated 
to circadian photoentrainment32,33.
In animal models of optic nerve injury and in human optic neuropathies, ipRGCs have shown a 
greater resistance to certain models of ganglion cell injury and death, compared to conventional retinal 
ganglion cells34–42. Several studies have observed that patients with bilateral visual loss due to mito-
chondrial dysfunction, such as the isolated hereditary optic neuropathies, retain normal pupil light 
reflexes39,43,44. Other types of ganglion cell death, such as glaucomatous optic neuropathy, do not appear 
to spare ipRGCs and melanopsin-mediated functions. Patients with moderate-to-advanced glaucoma 
demonstrate reduced pupil contraction and reduced PIPR, suggesting impaired signalling in the RTT45–47. 
In addition, they have a reduction in the light-induced suppression of nocturnal melatonin secretion and 
disturbances in sleep quality, implicating impairment of melanopsin signalling in the RHT pathway48–51.
These and other studies have examined the activity of ipRGCs in patients with visual loss from neu-
roretinal disease by assessing one parameter known to be modulated by the melanopsin system. However, 
it is not clear if all or only some of the melanopsin-based functions are altered in such patients and if 
they change with similar magnitude. We hypothesize that the physiologic functions related to acute light 
responses predominantly regulated by ipRGCs do show similar and proportionate compromise in the 
event of death or dysfunction of these cells. In this study, we examined the effect of optic nerve disease 
on the function and relationship of two mainly melanopsin-signalled functions, the pupil response and 
the suppression of the pineal hormone melatonin in response to bright light exposure in the evening. 
In addition to assessing the functional capacity of the RHT and RTT simultaneously, we also assessed 
cognitive parameters which are acutely influenced by bright light exposure, like subjective sleepiness, 
reaction time and working memory, in order to understand how dysfunction in one tract or both might 
relate to other downstream correlates of cognition and behaviour.
Results
Baseline measures. As projected for the study, differences in visual acuity (VA), mean deviation of 
the visual field (MD) and mean peripapillary retinal nerve fiber layer thickness (RNFL) between both 
patient and control groups were significant for all parameters (t-test; p < 0.05; Table  1). The patients 
having glaucoma (GL) were significantly older than the patients with hereditary optic neuropathy (HON; 
p < 0.009) and on average, GL patients had better VA than HON patients (p = 0.005). However, loss of 
visual sensitivity (estimated from visual field MD) and degree of optic atrophy (estimated from RNFL 
thickness) were comparable between patient groups (p > 0.1). Habitual wake- and bedtimes and sleep 
durations were not statistically different between groups (p > 0.06). Both patients groups had significantly 
higher scores on the Pittsburgh Sleep Quality Index (PSQI) than their controls (p < 0.041). Absolute 
Group Sex Age (yrs) WT HO PSQI BDI Pupil (mm) MD RNFL VA
HON Patients 4F 7M 39.4# (15.2) 6:49 (0:56) 58.1 (5.7) 4.4* (2.0) 1.7 (1.8) 4.88 (1.65) 7.3* (5.4) 63.9* 10.5) 0.4*,# (0.3)
GL Patients 8F 3M 54.1 (7.1) 6:11 (1:15) 62.0 (8.3) 5.5* (3.8) 2.2 (2.0) 4.61 (1.01) 11.4* (6.2) 59.8* (16.5) 0.7* (0.2)
HON Controls 8F 4M 36.2§ (13.2) 7:17 (0:40) 58.6 (9.6) 2.4 (1.9) 0.9 (1.0) 5.15 (1.28) − 0.7 (0.9) 104.5 (7.9) (0.1)
GL Controls 7F4M 54.4 (7.2) 7:02 (0:41) 59.4 (7.1) 2.8 (1.5) 1.6 (1.5) 4.99 (0.79) (0.8) 96.5 (13.1) 1.0 (0.1)
Table 1.  Demographics of patients with optic nerve disease (hereditary optic neuropathy HON and 
glaucoma GL) and their controls. Demographics for GL and HON Patients (Pat) and Controls of both 
groups; mean (± SD); N = 11 in each group. WT= habitual wake time (clock time); HO = Horne Ostberg; 
PSQI = Pittsburgh Sleep Quality Index; BDI = Beck Depression Inventory; MD = Mean Deviation of 
automated perimetry; RNFL = mean peripapillary retinal nerve fiber layer thickness (μ m); VA = Visual 
Acuity. *significant differences (p < 0.05) between patients and their controls (separately for GL and HON). 
#significant difference between both patient groups (p < 0.05). §significant difference between both control 
groups (p < 0.05). Absolute pupil sizes are indicated as mean values for all tests per participants and all 
ophthalmological values (pupil size, MD, RNFL, VA) were averaged for left and right eyes.
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pupil sizes during baseline recordings (i.e. first 10 s in darkness) were similar in both patient and control 
groups (p > 0.1), and there was no significant difference between left and right eyes (p > 0.1); therefore, 
both eyes were averaged for pupil analyses.
Melatonin. Salivary melatonin concentrations were analyzed relative to habitual wake times, with 
the first sample obtained approximately 11 hours after habitual wake time. Melatonin concentration was 
plotted as a function of time to ensure rising levels before light exposure (LE). Two GL patients showed 
no increase in salivary melatonin secretion before LE and were therefore not included in further mel-
atonin analyses. There were no differences in absolute melatonin concentrations (p > 0.5; effect sizes 
< 0.14) between patients and controls across all time points. In order to calculate melatonin suppression, 
melatonin concentrations during and after LE were expressed (as ratio) relative to the last concentration 
obtained before LE (Fig. 1). The HON and GL patients showed similar melatonin suppression when com-
pared to their controls (main effect of ‘group’; (HON: F1,20 = 0.16; p = 0.70; GL: F1,18 = 0.13; p = 0.72; effect 
sizes: < 0.13). Patients and controls showed a significant suppression during light exposure (main effect 
of ‘time’ without last sample point after lights off; HON: F1,20 = 54.46; and GL: F1,18 = 24.82; p < 0.0001).
Pupil results. The following abbreviations are used to express pupillary size (diameter) and vari-
ous aspects of the light response. The reader is referred to the supplement for full description of these 
pupil parameters. MPS = minimum pupil size, SPS = sustained pupil size, PSPS= post-stimulus pupil 
size, ERR = exponential re-dilation rate and ARS = asymptotic re-dilation size (ARS), see Fig.  2. SPS, 
PSPS, ERR and ARS are parameters which describe various aspects of pupillary dynamics in the 
post-illumination phase. In this study, the main measure of PIPR is the post-stimulus pupil size at 6 sec-
onds from light offset (PSPS).
The first and second pupil recordings, both performed in the same constant dim light (DL) condition, 
were averaged to obtain a single pre-light exposure (= pre-LE) pupil recording, and this was compared to 
the pupil recording obtained after 2 hr of bright light exposure (= post-LE). The absolute baseline pupil 
size was not different between pre-LE and post-LE recordings (p > 0.07). Overall, there were significant 
differences between red and blue light stimuli for all pupil measures analyzed, except for ARS such that 
after red light, the pupil tended to be less constricted and to re-dilate faster (= larger MPS, SPS and PSPS; 
fixed effect of ‘color’; separately tested for each of the four subgroups; F1,10 > 16.9; p < 0.003).
For red light stimuli, the MPS after 1 s and 30 s was smaller in HON patients and controls before 
bright light [main effect of pre-LE vs. post-LE; (F1,20 > 11.0; p < 0.003; Table  2, top]. There were no 
group differences for any of the red light stimuli between both patient groups and controls (F1,20 < 3.2; 
p > 0.08; Table 2 top; Fig. 3), except for a larger MPS and SPS (= less constricted pupils) after 30 s for the 
GL patients when compared to controls (F1,20 > 8.5; p < 0.009). For all patients and controls, the PSPS 
following red light in the pre-LE recording was significantly larger (= less constricted pupils) than that of 
the post-LE recording (main effect of pre-LE vs. post-LE; (F1,20 > 6.9; p < 0.02; Table 2, top). The ARS was 
larger for GL patients and controls before (pre-LE) than after bright light (post-LE; F1,20 = 12.2; p < 0.02 ).
Following blue light stimuli, GL patients had significantly larger MPS (i.e. less constricted pupils 
during 1 s and 30 s blue light stimuli; F1,20 > 5.7; p < 0.03), larger SPS (F1,20 = 6.2; p = 0.002) and PSPS 
Figure 1. Relative salivary melatonin concentrations for HON patients (left side) and GL patients (right 
side) and their controls before, during and after 2 hours of light exposure (LE) at night. Values are 
expressed relative to pre-light exposure melatonin concentrations. In response to light exposure (starting 
after 16 hours after habitual wake time), salivary melatonin was similarly suppressed in both patient groups 
(HON and GL) when compared to their controls (p > 0.6). Filled circles and solid lines = patients; open 
circles and dashed lines = controls. N = 11 in each group except for GL patients (N = 9; mean + SEM; grey 
areas indicate the light exposure).
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(after 1 s blue light ; F1,20 = 9.2; p = 0.007), smaller ARS (F1,20= 7.3; p= 0.01) and faster ERR after 30 s 
blue light stimuli (F1,20= 6.3; p = 0.02) compared to GL controls (main effect of ‘group’; Table 2, bottom). 
However, there were no group differences in these variables between HON patients and their controls 
(F1,20 < 1.99; p > 0.17), except for the MPS which was larger in HON patients than controls p = 0.041). 
In both groups (GL and HON), PSPS and MPS (after 1 s) were larger in the post-LE than the pre-LE 
recording (F1,20 > 5.1; p < 0.03; Table 2 bottom). Taken together, between patents and controls, only GL 
(but not HON) patients showed overall significantly larger PSPS, i.e., less persistent pupil contraction 
than their controls (p < 0.05) after blue light stimuli.
Lastly, we found that correlation of melatonin suppression with relative pupil size after blue light stim-
uli showed a significant positive association such that individuals who had greater melatonin suppression 
(i.e. lower salivary concentrations) also had greater post-stimulus pupil constrictions, i.e., had smaller 
PSPS (R2 = 0.14; p = 0.002; N = 42; Fig. 4).
Subjective Sleepiness. During the course of the evening both HON and GL groups and their con-
trols became sleepier (HON: F10,63 = 4.4 and GL: F10,53 = 2.32, respectively; p < 0.02; main effect of ‘time’). 
There was no absolute difference of subjective sleepiness between both patients groups and their controls 
across all measurements (p > 0.4; effect sizes < 0.34). During the light exposure, there was a signifi-
cant reduction of subjective sleepiness in both control groups (main effect of ‘time’; p < 0.02; Fig.  5a). 
There was, however, no main difference between GL or HON patients compared to controls (p > 0.2; 
effect sizes = 0.65 for GL and effect size = 0.09 for HON). The VAS scale was highly correlated to the 
KSS (R2 = 0.64, p < 0.05). By analysing the KSS we found that GL patients became significantly sleepier 
during LE than their controls (main effect of ‘group’; F1,16 = 7.3, p = 0.016; effect size = 0.43; Fig.  5b) 
and the co-variate ‘age’ was also significant (p = 0.0014), but there was no significant difference for the 
HON patients and controls (p= 0.7; effect size= 0.42; Fig. 5b). There was a significant interaction for the 
HON and GL controls with both VAS and KSS (VAS: F3,30 = 4.36; KSS: F3,28 = 3.29; p = 0.035) during 
light exposure and post-hoc analysis (Tukey-Rank Tests adjusted for multiple comparisons) showed that 
despite an overall reduction of sleepiness especially during the first hour of bright light, HON controls 
became again sleepier after this first hour (p = 0.02), without any other differences between the two 
control groups.
Psychomotor Vigilance Test (PVT). The absolute median reaction times (RT) in the Psychomotor 
Vigilance Test (PVT), the 10% slowest and 10% fastest percentile) revealed no difference between HON 
and GL patients and their controls (HON: F1,10 < 0.73; p > 0.43; effect sizes < 0.25; HON patients: 
246.0 ± 31 ms; HON controls: 250.6 ± 45 ms; means for all tests ± SD; GL: F1,7 < 3.0; p > 0.13; effect sizes 
< 0.15; GL patients 268.8 ± 34 ms: GL controls: 239.4 ± 29 ms; means for all tests ± SD). There were no 
significant differences between HON and GL patients and their controls for lapses (i.e. RTs > 500 ms; 
p > 0.15; Mann-Whitney U Test). For both patient groups and their controls there was no effect of the 
factor ‘time’ or any interaction between the factors ‘group x time’ (p > 0.11). When we compared median 
Figure 2. Pupillogram with all metrics and legend with abbreviations The schematic of the protocol 
from one recording with the following variables is shown: BL = Baseline pupil size (pupil diameter 
during the first 10 s of recording in darkness = 100%). Pupil size was expressed relative to baseline (actual 
pupil diameter/BL pupil diameter*100). MPS = Minimum Pupil size during 1 s and 30 s light stimuli (red 
and blue); PSPS = Post-Stimulus pupil size at 6 s after 1 s stimulus offset (red and blue); SPS = sustained pupil 
size; ERR = Exponential redilation rate after 30 s stimulus offset (%− s); ARS = Asymptotic re-dilation size 
after 30 s light blue and red light stimuli. The bold colored arrows at the top indicate the 1 s red and blue 
light stimuli as well as the 30 s red and blue light stimuli.
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RT during LE relative to pre-LE (ratios), HON and GL patients showed median RT that was similar to 
their controls (HON: p = 0.76; effect size = 0.37; GL: p = 0.22; effect size = 0.32), and there were also 
similar results for the slowest 10% RT in HON and GL patients and their controls (p > 0.29; effect sizes 
< 0.51 ). For the fastest 10% RT, only GL patients were significantly slower during LE than their controls 
(F1,5 = 14.5; p = 0.013; effect size= 0.66 Fig. 6); for HON patients and their controls there was no differ-
ence (F1,5 = 0.11; p = 0.75; effect size = 0.43 Fig. 6). Unexpectedly, HON controls were significantly slower 
than GL controls during LE until 1h after LE (relative to pre-light; main effect of ‘group’; F1,4 = 58.95; 
p = 0.002) and the co-variate age also became significant (p = 0.005); but there was no difference between 
the two patient groups (F1,2 = 0.36; p = 0.61).
Red Lights
Controls Patients
Mean 
Pre-LE (SD)
Mean % 
Post-LE (SD)
Mean 
Pre-LE (SD)
Mean 
Post-LE (SD)
GL
 MPS (1s) 55.5 (4.8) 56.6 (8.2) 60.9 (6.6) 60.9 (8.1)
 MPS (30s)* 40.7 (8.0) 43.5 (3.6) 48.7 (4.9) 49.5 (6.4)
 SPS (30s)* 48.2 (5.3) 50.4 (5.2) 55.3 (6.3) 56.5 (7.0)
 PSPS (1s)# 92.8 (6.1) 89.7 (8.8) 95.3 (4.2) 90.9 (8.2)
 ERR (30s) − 4.78 (0.06) − 4.80 (0.06) − 4.81 (0.08) − 4.87 (0.11)
 ARS (30s)# 107.0 (8.3) 104.8 (9.7) 104.7 (5.3) 97.7 (7.8)
HON
 MPS (1s)# 59.2 (4.6) 62.9 (5.2) 57.1 (6.9) 61.0 (6.4)
 MPS (30s)# 43.2 (3.0) 47.3 (4.6) 44.1 (4.4) 46.3 (6.7)
 SPS (30s) 53.5 (6.0) 54.3 (5.5) 51.2 (4.9) 52.3 (6.2)
 PSPS (1s)# 95.5 (4.0) 89.2 (5.4) 94.1 (5.3) 91.6 (4.9)
 ERR (30s) − 4.82 (0.10) − 4.82 (0.07) − 4.78 (0.10) − 4.86 (0.15)
 ARS (30s) 105.1 (7.4) 100.7 (3.8) 109.1 (17.6) 103.1 (8.6)
Blue Lights
GL
 MPS (1s)*,# 46.9 (7.5) 50.1 (6.1) 53.7 (4.0) 55.9 (7.2)
 MPS (30s)* 36.3 (8.2) 37.9 (4.8) 43.6 (4.0) 43.6 (5.3)
 SPS (30s)* 37.6 (7.7) 37.4 (5.1) 45.6 (4.3) 44.2 (5.7)
 PSPS (1s)*,# 56.5 (8.4) 64.2 (9.9) 66.4 (7.3) 73.6 (8.9)
 ERR (30s)* − 4.67 (0.03) − 4.67 (0.04) − 4.70 (0.07) − 4.75 (0.05)
ARS (30s)* 106.4 (14.0) 104.0 (7.6) 96.9 (13.1) 98.6 (8.6)
HON
 MPS (1s)# 46.1 (2.2) 52.2 (4.4) 48.9 (5.3) 53.1 (5.0)
 MPS (30s)* 36.9 (2.8) 37.3 (4.7) 38.6 (3.6) 42.0 (5.8)
 SPS (30s) 38.3 (3.5) 38.4 (3.2) 40.7 (4.1) 40.7 (3.8)
 PSPS (1s)# 55.6 (4.7) 68.4 (7.6) 62.7 (8.1) 69.0 (8.3)
 ERR (30s) − 4.72 (0.10) − 4.69 (0.03) − 4.72 (0.11) − 4.75 (0.10)
 ARS (30s) 103.1 (7.6) 104.6 (14.5) 104.3 (13.2) 103.4 (8.3)
Table 2.  Pupil parameters for patients with optic nerve disease (hereditary optic neuropathy HON 
and glaucoma GL) and their controls (N = 44). Results of the PLR to red (at the top) and blue light (at 
the bottom) before (= pre-LE) the 2-hrs of bright light exposure and after constant bright light (post-LE). 
MPS = minimum pupil size for 1 s and 30 s light stimuli; SPS: sustained pupil size at the end of the 30 s 
stimulus; PSPS = post-stimulus pupil size after 1 s light stimuli; ERR = exponential re-dilation rate after 30 s 
stimuli (%-s); ARS = asymptotic re-dilation pupil size for the exponential fitting. All values are shown ± SD 
(in brackets) and for controls left side and patients (right side). Results for glaucoma (GL) patients and 
controls are shown in the first four rows and results for hereditary optic neuropathy (HON) patients and 
controls are shown in the lower four rows. *Significant difference between controls and patients within a 
group (GL or HON). #significant difference between pre-LE and post-LE (p < 0.05; N = 44).
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Auditory n-back task. The auditory n-back test showed no overall difference in accuracy and reac-
tion time (RT) of the 0-back within both patient groups and their controls (p > 0.2; effect sizes < 0.36), 
indicating that all participants responded properly in pressing a key when no working memory task was 
involved. There were no differences between the two control groups for any test but in the 2-back test, 
the controls of the HON group showed significantly better performance than HON patients (main effect 
of ‘group’; F1,5 = 7.4; p = 0.042; effect size = 0.80). There was no difference in accuracy between the GL 
patients and controls (F1,5 = 1.9; p = 0.2; effect size = 0.43). In the 3-back test, HON controls performed 
again more accurately than HON patients (F1,5 = 6.95; p = 0.046; effect size = 1.08) and this was also 
Figure 3. (a,b) Averaged (from three recordings) pupil tracings for the 1 s (a) and 30 s (b) red and blue 
light stimuli for HON patients (upper graphs) and GL patients (lower graphs) and their controls (black 
lines = patients; N = 11/11; grey lines = controls; N = 11/11). The vertical dashed line indicates the 
approximate pupil size 6s after light termination (= PSPS). A significant difference was observed between GL 
patients and controls but between not HON patients and controls (p < 0.05). For more results, see Table 2.
Figure 4. Spearman Correlation between post-stimulus pupil size in response to 1 s blue light (relative 
to baseline) and mean salivary melatonin concentration (relative to pre-light exposure). Smaller 
melatonin concentrations indicate greater melatonin suppression; N = 42 (grey circles). The black line shows 
the regression line (Correlation R2 = 0.14; p = 0.002).
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a trend for the GL control group (F1,5 = 4.3; p = 0.097; effect size = 0.72). HON patients and controls 
became worse in the course of the study in the 2- and 3-back test and had lower accuracy after LE than 
at the beginning of the study (2-back: F4,78 = 2.64; p = 0.04; 3-back: F4,78 = 4.28; p = 0.0035; main effect 
of ‘time’). Besides the above mentioned differences between groups, there were no specific improvements 
during light exposure for the 2- or 3-back in any of the groups, when the last session after LE was com-
pared to the pre-LE session (p > 0.6).
Discussion
We aimed at assessing two physiologic functions driven by two different but mainly melanopsin-dependent 
pathways, i.e., melatonin suppression and the pupil light response (PLR), in visually impaired patients 
with glaucoma (GL), and with hereditary optic nerve disease (HON). The results were compared to 
healthy age-matched controls.
Our results on melatonin suppression for HON patients agree with results from another study40, 
such that HON patients and controls responded with similar melatonin suppression to nocturnal light 
exposure. This preservation of RHT function is thought to be due to selective sparing of ipRGCs in this 
Figure 5. (a,b) Subjective sleepiness in patients and controls during and after light exposure (difference 
to pre-light exposure) assessed from (a). Visual analogue scales (VAS) and (b). Karolinska sleepiness 
scale (KSS) in patients (filled circles, solid lines) and controls (open circles, dashed lines). HON patients 
and their controls are shown on the left side; GL patients and their controls are shown on the right side. 
From the VAS, HON patients and controls acutely responded to light exposure (p < 0.05; main effect of 
time), but there was no significant difference in sleepiness between HON and GL patients and controls 
(means + or − SEM; grey area = light exposure) during and after LE. From the KSS, GL patients became 
significantly sleepier during LE compared to controls. HON patients respond similarly as their controls.
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particular disorder in which a mitochondrial gene mutation is related to retinal ganglion cell death40. 
However, results on melatonin suppression from our GL patient group did not corroborate findings 
from other studies48,49. One study of 9 glaucoma patients demonstrated attenuated melatonin suppression 
under bright (600 lx) light exposure48, whereas in our GL patients, melatonin suppression to bright light 
(4000 lx) was similar to healthy age-matched controls. How could these differences be interpreted? One 
simple reason may be differen es in cohort characteristics and methodology. Our glaucoma patients 
were younger with less severe disease. In addition, we ensured the timing of melatonin secretion by use 
of hourly melatonin sampling over a 10 hour period of extended wakefulness in entrained patients, as 
opposed to a single pre-light and post-light melatonin sample at the fixed time of the night. An alterna-
tive explanation may lie in the light intensity such that with lower illuminance, we might have observed 
distinct differences between GL patients and controls as hypothesized.
In a rodent model of glaucoma, it has been shown that animals with binocularly induced chronic high 
intraocular pressure took significantly longer than control animals to entrain to light-dark cycles at low 
illuminances (1–10 lx) but not at higher illuminances (10–100 lx), even though all animals were able to 
entrain48. From this animal model of glaucoma arises evidence of an attenuated circadian response that 
is evident only at lower light intensities. We may assume that, in our study, overall photic integration of 
bright light intensity (4000 lx) and a 2 h exposure duration led to saturation for melatonin suppression. 
Perhaps at lower intensities (or shorter exposure duration), our GL patients may have demonstrated an 
attenuated suppression of nocturnal melatonin. In addition, the stage of disease was mild to moderate for 
GL patients in our study. In the previously mentioned study, the GL patients had more advanced disease 
and this might translate into greater loss of ipRGCs48.
The dim light pupil responses to red and blue light showed expected results. The immediate pupil 
constriction to blue light was greater than that to an equivalent red light. This is a consistent finding, 
previously reported by us and others23,24,52,53, which is presumably and in part due to a greater participa-
tion of rods to the immediate pupil constriction to abrupt light onset. After termination of the blue light, 
the pupil tended to remain contracted, whereas after termination of the red light, the pupil re-dilated 
quickly and almost reached its baseline size within 6 seconds. Several studies have shown that the spec-
tral sensitivity of the post-illumination pupil response (PIPR) matches that of melanopsin pigment18,22,25 
and thus we consider persistently small pupils following blue light offset in this study to be a marker of 
melanopsin contribution to the pupil light reflex. The post-stimulus pupil size (PSPS) was not affected 
in the HON group but glaucoma patients had pupils that were less able to sustain contraction following 
light offset (larger PSPS). Indeed, all parameters of the PIPR were significantly reduced in glaucoma 
patients. While there were differences in pre-LE and post-LE pupil responses for both red and blue lights, 
such changes most likely relate to light adaptation effects from all photoreceptive components, enabled 
via dopaminergic amacrine cells16. Other studies have also shown a loss of the PIPR in patients with 
moderate to advanced glaucoma45–47,54,55. Our study demonstrates that potential ipRGC dysfunction and 
thus reduced melanopsin activity occurs even in earlier stages of this disease. Our glaucoma patients had 
Figure 6. Changes in the 10% fastest reaction times (ms) in the Psychomot r Vigilance Test (PVT) 
during and after light exposure for HON patients (left side) and GL patients (right side) and their 
controls. The N = 11 in each group except for GL patients: N = 8; filled circles and solid lines = patients; 
open circles and dashed lines = controls. The 10% fastest reaction times (ms) were similar for HON 
patients and controls (relative to pre-light exposure), but GL patients were significantly slower than their 
controls in response to bright LE (bottom right side; N = 11 in each group except for GL patients: N = 8; 
filled circles = patients; open circles = controls; *< 0.05). Grey bars indicate constant bright light exposure 
(means + or – SEM).
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only moderate deficits on visual field testing and visual acuity. In contrast, HON patients with similar 
degree of visual loss but of different pathophysiology, i.e. inherited mitochondrial dysfunction, did not 
demonstrate any reduction of melanopsin activity as determined from PIPR analysis using 1 s or 30 s of 
light stimulation. Relative resistance of ipRGCs to mitochondrial dysfunction and cell death has been 
demonstrated histopathologically in patients with HON and is generally cited as the reason for the pres-
ervation of melanopsin-mediated light functions in these patients38,39,56.
We had hypothesized that both circadian and pupillary function (mediated via the RHT and RTT of 
ipRGCs) would be similarly and proportionately affected by ocular disease causing retinal ganglion cell 
loss, as a relationship between melatonin and pupil over 24 hours has been reported in previous works in 
humans53,57. In the current study, there is indeed a weak but significant positive correlation between the 
functions mediated by these two tracts. In other words, a greater ability to suppress nocturnal melatonin 
in response to acute bright light was correlated with a greater ability to keep the pupils contracted after 
light offset in the same individual. Thus it is not surprising that patients with HON, a disease believed 
to spare ipRGCs, had no loss in either RHT or RTT function.
To be fair, the correlation was weak (R2 = 0.14) and this may indicate potential sources of variance 
on melatonin secretion and pupillary contraction. These include central modulating influences at the 
multiple synaptic sites of the two pathways. Since we did not find statistical differences in melatonin 
suppression between both control groups and their patients but significant differences in pupil responses, 
the intra-individual correlation may not exist. Perhaps melatonin secretion and the pupil light reflex in 
response to light are functionally different processes and this may be the basis for the unexpected finding 
that glaucoma patients in this study showed a relative loss of the pupil function but not the melatonin 
function. In contrast, in more advanced stages of disease, patients with glaucoma have shown loss of 
melatonin suppression48. So why might dissociation in the functional activity of RHT vs. RTT manifest 
in earlier stages of disease?
One possible reason might be a differential number of ipRGC projections in the RHT compared to the 
RTT, and this may relate to a differential sensitivity between melatonin suppression and pupil light reflex 
for detection of dysfunction. If the RHT has a greater number of axons, as indicated in an animal model 
of glaucoma51,55, there may be enough redundancy in the circadian system such that mild-to-moderate 
optic atrophy from glaucoma does not yet affect melatonin responses whereas the RTT and pupillary 
function might be more susceptible to early loss of ipRGCs.
Another reason may be related to ipRGC subtypes. Despite their scarce numbers, there is surprising 
diversity in their anatomic morphology, molecular expression and kinetics of photic response26–31. In 
mice, at least 5 subypes of ipRGCs have been identified. The two most populous are M1 and M2 subtypes, 
found in fairly equivalent proportions27,58,59, and display different photic responses. The M1 subtype 
responds to light mostly via melanopsin-based photoreception28,29 whereas M2 subtype generate mostly 
extrinsic synaptically-driven photoresponses. In addition, there is diversity in the central projections 
of ipRGCs. In the RHT, light input from the M1 subtype of ipRGCs dominates whereas M2 input may 
be slightly more favoured in the RTT28,58,60. If M2 subtype of ipRGCs is more susceptible to glaucoma, 
or alternatively if M1 subtype is a more robust subtype, then loss of pupillary function may be evident 
earlier in disease compared to the RHT function which may remain spared until more advanced cell 
death occurs.
A third reason may be simply that the RHT and RTT do not synapse directly at the efferent nuclei 
for melatonin secretion and pupil light reflex. The RHT and RTT serve as a direct source of retinal light 
information to the suprachiasmatic and the pretectal olivary nuclei, which are the main integrating nuclei 
for ircadian rhythm and pupil light reflex, respectively. These nuclei also receive various other supra-
nuclear inputs which modulate their signaling through multisynaptic pathways to regulate for example 
melatonin secretion via the pineal gland and to initiate pupillary constriction via third crania nerve. 
Even if glaucoma does disrupt signaling through both the RHT and RTT, perhaps there are more central 
influences or adaptive mechanisms aimed to maintain melatonin secretion at normal functioning.
Attenuation of other non-visual functions in patients with ipRGC cell loss such as in GL patients 
were shown by lessening of acute alerting effects to bright light exposure on subjective sleepiness and 
reaction times in the PVT. This is an indication that other central influences on alerting and cognitive 
functions were selectively impaired in patients with ipRGC cell losses, as recently shown also on sleep 
with lower sleep efficiency in glaucoma patients than healthy controls54,. We were not able to find acute 
light effects in one of the two patient-control groups to an auditory working memory test. It seems that 
patients, especially HON patients performed overall worse than their controls which possibly indicates 
that either the test was too difficult and/or patients were altogether too sleepy. Additionally, the small 
sample size of this study may have precluded finding an effect.
To summarize we found preserved melatonin suppression in GL and HON patients, but only GL 
patients had larger PSPS (reduced PIPR) when compared to their controls. In glaucoma, this dissociation 
of disease effect on melanopsin-mediated functions may arise from several factors including relatively 
early disease state, selective impact or sensitivity amongst ipRGC subtypes to disease or asymmetric 
influence of central modulating inputs on the pupil and circadian response. In addition, during bright 
light exposure, GL patients were sleepier with slower reaction times compared to controls suggesting that 
there may be an influence of reduced ipRGC signaling on cognitive and behavioural functions.
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Methods
Study design. Each participant came to the eye hospital once during daytime for baseline ophthal-
mological examination. At this visit, participants were also trained for the cognitive testing, underwent a 
baseline pupil recording and received instructions for use of the activity monitor. Thereafter, participants 
were asked to maintain a regular sleep wake-cycle during one week prior to the study. This included 
moderate consumption of caffeine and alcoholic beverages and a sleep schedule of approximately 8 hours 
in bed at the same times each night (within a range of 30 minutes). Compliance with the latter was ver-
ified by wearing a wrist activity monitor (Actiwatch L, Respironics AG, Schweiz) and maintenance of a 
sleep diary.
At the end of the entrainment period, participants were asked to come to the photo biological labora-
tory at the Swiss Federal Institute of Lausanne during evening time for the study testing. Each participant 
was individually tested on a different night. Compliance for medication and drug absence was verified 
with a urinary toxicological screen before the night testing. The study testing started 10 hours after habit-
ual wake time and lasted for 10 hours. Room lighting was maintained at a constant dim illumination 
(< 6 lx). Participants were able to talk and to listen to music or audio books. Portable electronic appli-
ances with screens were not permitted due to the additional light exposure. Small meals and water were 
provided on a scheduled basis. Throughout the 10 hours in the laboratory, the participants were regularly 
asked to rate their level of sleepiness. Throughout the evening, salivary samples were collected in a plastic 
cup every hour; the first sample was obtained approximately 11 hours after habitual wake time. Every 60 
to 120 minutes the participants performed two auditory cognitive performance tests.
For the first 7 hours, the participant remained seated in dim light conditions (< 6 lx). After 7 hours, 
the participant was exposed to 2 h of polychromatic white bright light and then sat in DL again for the 
last hour of the study. The experimental 2 hours of polychromatic bright light exposure (LE) for the mel-
atonin suppression test started 17 hours after their habitual wake time. For this purpose, the participant 
was seated in front of a large light screen (1.57 × 1.22 m) at 0.5 m distance and contained fluorescent 
tubes [34 FL tubes; TLD 50W/94 HF; (Philips) see supplemental Figure S1 for spectral characteristics of 
the light source]. Participants were instructed to keep their eyes open and to look towards the screen. 
The illuminance at the eye level in a vertical direction was set to be 4000 lx and was verified for each 
participant during LE. Two times before, and immediately after LE, a PLR was recorded on both eyes. 
Every 60–120 minutes the participants performed two auditory-based cognitive performance tests (see 
below). Compliance with all study procedures was verified by a trained person who was present through-
out the study in the same room. All study participants provided oral and written informed consent 
for study participation. Study procedures were reviewed and approved by the local ethical commission 
(Commission d’Ethique de Recherche sur l’être humain de Canton de Vaud, Switzerland) and were in 
accordance with the Declaration of Helsinki. Detailed information on the methods as described above, 
the statistics, the screening procedures and inclusion criteria for patients with hereditary optic nerve 
disease (n = 11) and glaucoma (n = 11); as well as age-matched controls (n = 22), can be found in the 
supplemental document (p S1–S13).
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